non-Hodgkin's lymphomas

... have one of the covered conditions: bladder cancer, breast cancer, esophageal cancer, female infertility, hepatic steatosis, kidney cancer, leukemia, lung cancer, miscarriage, multiple myeloma, Myelodysplastic syndromes, neurobehavioral effects, non-Hodgkin's lymphoma, renal toxicity and scleroderma ...

The global non-hodgkin lymphoma therapeutics market has been estimated to reach USD 7.45 billion in 2023. The market is expected to register a CAGR of 7.4% during the forecast period 2018 to 2023. North America dominates the market due to the increasing technological advancements.

SALT LAKE CITY — The chimeric antigen receptor T-cell therapy axicabtagene ciloleucel induced significant clinical benefit with manageable adverse events among patients with refractory aggressive non-Hodgkin lymphoma, according to long-term follow-up of the pivotal ZUMA-1 clinical trial presented at ...

A study to be presented at the BMT Tandem Meetings (February 21-25, 2018; Salt Lake City, UT) found no difference in overall survival (OS) for patients aged 55-64 years compared with those aged 65 years and older with non-Hodgkin lymphoma (NHL) who underwent allogeneic hematopoietic stem cell ...

Results from a retrospective study of 1,629 patients with non-Hodgkin lymphoma (NHL) showed that survival at 4 years following allogeneic hematopoietic cell transplantation (HCT) for patients age 65 years and older is comparable to patients age 55 to 64 years. The study demonstrates that age alone ...

OTTAWA -- Liberal MP Salma Zahid says she's taking a medical leave to be treated for non-Hodgkin's lymphoma. Zahid, who represents a Toronto-area riding, says she received the diagnosis in the last week. It followed weeks of intermittent pain that began after an overseas visit during the holidays.

Neelapu and colleagues demonstrated that more than half of patients with refractory, aggressive non-Hodgkin lymphoma remained alive at least 1 year after receiving a single infusion of anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead Sciences).

Direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infection was well tolerated and appeared synergistic with chemotherapy of comorbid non-Hodgkin's lymphoma (NHL). The risk for NHL is increased with HCV infection, and successful treatment of HCV with pre-DAA era treatments has been ...

Oliver was diagnosed with non-Hodgkin's lymphoma at just six years old and the brothers found themselves in hospital beds next to one another, battling cancer together. Their mum revealed at first the family all just hoped it was some kind of error. Ms Redfearn, from Wakefield in West Yorkshire, said: “If ...

Although allogeneic hematopoietic stem cell transplantation (HCT) is a potentially curative therapy for patients with non-Hodgkin lymphoma (NHL), there is a lack of Medicare coverage, which has resulted in limited use among patients age 65 years or older. New research presented by investigators at the ...